RxDoctor Payments Data

Steven Furr, MD

Family Medicine · Jackson, ALNPI 1639179609

Payments from drug & device makers

$1,651in general payments, 2019–2025

Across 98 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$673
  • Johnson & Johnson$206
  • AstraZeneca$155
  • Boehringer Ingelheim$98
  • Lilly USA, LLC$64
  • Abbott$56
  • plus $399 from 13 others

What the payments were for

  • Food & beverage$1,651100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,651 in reported general payments places this provider in the 65th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$4,752
Medicare patients
172
Services billed
380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate189$158,109
FarxigaDapagliflozin Propanediol52$55,044
EliquisApixaban56$47,341
OzempicSemaglutide46$44,050
RybelsusSemaglutide42$43,055
JardianceEmpagliflozin51$29,805
Bydureon BciseExenatide Microspheres24$24,352
MounjaroTirzepatide15$17,602
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$16,013
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog21$15,352
GemtesaVibegron26$12,623
EntrestoSacubitril/Valsartan13$9,431
Combivent RespimatIpratropium/Albuterol Sulfate15$8,094
Breo ElliptaFluticasone/Vilanterol19$7,997
JanumetSitagliptin Phos/Metformin Hcl11$7,382

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$673$90,099100 claims
AstraZenecaFarxiga$155$55,04452 claims
PfizerEliquis, Premarin$32$50,23969 claims
Boehringer IngelheimJardiance, Combivent Respimat$98$37,89966 claims
GSKTrelegy Ellipta, Breo Ellipta$35$24,01142 claims
Lilly USA, LLCMounjaro, Olanzapine$64$20,52957 claims
NovartisEntresto$50$9,43113 claims
AbbVieSynthroid$48$1,98120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Jackson

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →